Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors

被引:19
|
作者
Kanamori, Masayuki [1 ]
Kumabe, Toshihiro [1 ]
Sonoda, Yukihiko [1 ]
Nishino, Yoshikazu [2 ]
Watanabe, Mika [3 ]
Tominaga, Teiji [1 ]
机构
[1] Tohoku Univ, Grad Sch Med, Dept Neurosurg, Aoba Ku, Sendai, Miyagi 9808574, Japan
[2] Miyagi Canc Ctr, Res Inst, Div Epidemiol, Natori, Miyagi 9811293, Japan
[3] Tohoku Univ, Grad Sch Med, Dept Pathol, Sendai, Miyagi 9808574, Japan
关键词
Oligodendroglioma; Dissemination; Predictive factors; Nestin Ki-67; LOW-GRADE OLIGODENDROGLIOMAS; PHASE-III TRIAL; GLIOBLASTOMA-MULTIFORME; PROGNOSTIC-SIGNIFICANCE; EXPRESSION; GLIOMAS; CHEMOTHERAPY; RADIOTHERAPY; MARKERS; NESTIN;
D O I
10.1007/s11060-008-9762-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The pattern of recurrence and predictive factors for tumor progression, dissemination and survival in oligodendroglial tumors were investigated. 56 consecutive patients with oligodendroglial tumors were retrospectively analyzed to determine the predictive significance of various factors, including World Health Organization grade, loss of chromosomes 1p and 19q, and immunohistochemical features of TP53, O-6-methylguanine-deoxyribonucleic-acid-methyltransferase, CD44H, nestin, and Ki-67. Eleven patients developed dissemination, and had significantly shorter post-progression survival compared to ten patients with local recurrence. Univariate analysis showed that retention of chromosome 1p or 19q, Ki-67 labeling index a parts per thousand yen 25%, diffuse expression of nestin, and p53 labeling index a parts per thousand yen 10% were unfavorable factors for overall, progression-free, and dissemination-free survival. Multivariate analysis showed that Ki-67 labeling index a parts per thousand yen 25% and diffuse expression of nestin were significant for dissemination-free survival. In conclusion, post-progression survival shows significant differences between patients with local and disseminated recurrence. Ki-67 labeling index and nestin expression pattern are useful markers to predict dissemination.
引用
收藏
页码:219 / 228
页数:10
相关论文
共 50 条
  • [41] Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
    Imai, Hisao
    Mori, Keita
    Wakuda, Kazushige
    Ono, Akira
    Akamatsu, Hiroaki
    Shukuya, Takehito
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Kaira, Kyoichi
    Murakami, Haruyasu
    Endo, Masahiro
    Nakajima, Takashi
    Yamamoto, Nobuyuki
    Takahashi, Toshiaki
    ANNALS OF THORACIC MEDICINE, 2015, 10 (01) : 61 - 66
  • [42] Overall survival and progression-free survival in patients with primary brain tumors after treatment: is the outcome of [18F] FDOPA PET a prognostic factor in these patients?
    Chiaravalloti, Agostino
    Esposito, Vincenzo
    Ursini, Francesco
    Di Giorgio, Eugenio
    Zinzi, Maddalena
    Calabria, Ferdinando
    Cimini, Andrea
    Schillaci, Orazio
    ANNALS OF NUCLEAR MEDICINE, 2019, 33 (07) : 471 - 480
  • [43] Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC
    Rutkowski, Jacek
    Saad, Everardo D.
    Burzykowski, Tomasz
    Buyse, Marc
    Jassem, Jacek
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (09) : 1619 - 1627
  • [44] Factors that Influence 2-Year Progression-Free Survival Among Head and Neck Cancer Patients
    Irawan, Cosphiadi
    Benbella, Larangga Gempa
    Rachman, Andhika
    Mansjoer, Arif
    JOURNAL OF EPIDEMIOLOGY AND GLOBAL HEALTH, 2022, 12 (01) : 16 - 24
  • [45] Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer
    Hirai, Takehiro
    Nemoto, Asuka
    Ito, Yoshinori
    Matsuura, Masaaki
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 181 (01) : 189 - 198
  • [46] Surrogacy of tumor response and progression-free survival for overall survival in metastatic breast cancer resistant to both anthracyclines and taxanes
    Matsubara, Yoshihiro
    Sakabayashi, Satomi
    Nishimura, Tsutomu
    Ishida, Takanori
    Ohuchi, Noriaki
    Teramukai, Satoshi
    Fukushima, Masanori
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2011, 16 (06) : 623 - 629
  • [47] Radiotherapy with targeted and immunotherapy improved overall survival and progression-free survival for hepatocellular carcinoma with portal vein tumor thrombosis
    Ma, Jianing
    Zhang, Haifeng
    Zheng, Ruipeng
    Wang, Shudong
    Ding, Lijuan
    ONCOLOGIST, 2024,
  • [48] Nomograms for predicting progression-free survival and overall survival after surgery and concurrent chemoradiotherapy for glioblastoma: a retrospective cohort study
    Zheng, Lin
    Zhou, Zhi-Rui
    Shi, Minghan
    Chen, Haiyan
    Yu, Qian-Qian
    Yang, Yang
    Liu, Lihong
    Zhang, Lili
    Guo, Yinglu
    Zhou, Xiaofeng
    Li, Chao
    Wei, Qichun
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (07)
  • [49] Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
    Gainor, Justin F.
    Tan, Daniel S. W.
    De Pas, Tomasso
    Solomon, Benjamin J.
    Ahmad, Aziah
    Lazzari, Chiara
    de Marinis, Filippo
    Spitaleri, Gianluca
    Schultz, Katherine
    Friboulet, Luc
    Yeap, Beow Y.
    Engelman, Jeffrey A.
    Shaw, Alice T.
    CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2745 - 2752
  • [50] Evaluation of reproducibility in MRI quantitative volumetric assessment and its role in the prediction of overall survival and progression-free survival in glioblastoma
    Blomstergren, Adam
    Rydelius, Anna
    Abul-Kasim, Kasim
    Latt, Jimmy
    Sundgren, Pia C.
    Bengzon, Johan
    ACTA RADIOLOGICA, 2019, 60 (04) : 516 - 525